Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on January 17, 2025, reports a material change in major shareholdings for Haleon Plc. The filing discloses a reduction in Pfizer Inc.'s voting rights stake in Haleon following a secondary offering of ordinary shares.
Key Financial Metrics and Shareholding Data
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on equity ownership changes.
- Issuer: Haleon Plc
- Shareholder: Pfizer Inc.
- Transaction Date: January 17, 2025
- Shares Sold: 700,000,000 ordinary shares
- Previous Voting Rights: 15.04% (approx. 1.36 billion shares)
- Current Voting Rights: 7.31% (661,709,764 shares)
- Total Issued Voting Capital: 9,053,360,882 ordinary shares
Material Changes Versus Prior Period
Pfizer Inc. reduced its total voting rights in Haleon from 15.04% to 7.31%. This change resulted from the sale of 700,000,000 ordinary shares pursuant to a secondary offering announced on January 14, 2025. The transaction was completed on January 17, 2025, in New York, USA.
Outlook, Risks, and Management Commentary
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. It is a statutory notification of a change in major holdings under UK Disclosure Guidance and Transparency Rules (DTR).
Key Facts for Investor Verification
- Verify the exact number of shares sold (700,000,000) and the price per share in the secondary offering announced on January 14, 2025.
- Confirm Pfizer's remaining strategic intent regarding its 7.31% stake in Haleon.
- Review the total issued voting share capital of 9,053,360,882 as of November 1, 2024, to ensure no subsequent capital changes have occurred.
- Check for any lock-up agreements or future sale plans associated with the remaining Pfizer holdings.